Langerhans-cell Histiocytosis and Thalidomide: An efficacious option? First case report in Cuba

Authors

  • Adys Idalia Gutiérrez Díaz Hospital Provincial Universitario Pediátrico "Eliseo Noel Caamaño".Matanzas
  • Aramis Núñez Quintana Instituto de Hematología. La Habana
  • Ileana Nordet Carrera Instituto de Hematología. La Habana
  • Alejandro González Otero Instituto de Hematología.La Habana
  • Luis Ramón Rodríguez Instituto de Hematología. La Habana
  • Juan Carlos Jaime Fagundo Instituto de Hematología. La Habana

Keywords:

HISTIOCYTOSIS, LANGERHANS-CELL, THALIDOMIDE, RHO(D) IMMUNE GLOBULIN, DEXAMETHASONE, HUMAN, CHILD

Abstract

Langerhans-cells Histiocytosis is a rare disease characterised by a monoclonal proliferation of Langerhans-cells. It's an entity with a very wide clinic spectre. The therapeutic options have passed from the usage of conventional antineoplastic agents to the inmunomodulatory agents like thalidomide, though the experience of this drug usage against that disease in children is very limited. In this work we present a three-years-old patient diagnosed with risk multisystemic Langerhans-cell histiocytosis in a second progression, rescued with antitimocitic globulin and dexametasone. We used thalidomide as maintenance and it was suspended transitorily. In this short period the disease activated again and was controlled with its reintroduction. The eight-month's evolution has being satisfactory, with a good tolerance and without signs and symptoms of the disease.

Downloads

Download data is not yet available.

Downloads

How to Cite

1.
Gutiérrez Díaz AI, Núñez Quintana A, Nordet Carrera I, González Otero A, Ramón Rodríguez L, Jaime Fagundo JC. Langerhans-cell Histiocytosis and Thalidomide: An efficacious option? First case report in Cuba. Rev Méd Electrón [Internet]. 2014 Mar. 3 [cited 2025 Feb. 5];30(2):255-60. Available from: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/493

Issue

Vol. 30 No. 2 (2008)

Section

Presentation of cases

License

All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.

It allows:

 - Copy and redistribute published material in any medium or format.

 - Adapt the content.

 This will be done under the following terms:

 - Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.

 - Non-commercial use.

 - Recognize the journal where it is published.

 The copyrights of each article are maintained, without restrictions.

Most read articles by the same author(s)